Evonik and Shandong Vland Biotech have established a joint venture, Evonik Vland Biotech (Shandong) Co., Ltd., with Evonik as the majority shareholder, holding 55% of the shares. The partnership will focus on advancing gut health solutions for farm animals, including probiotics.
Evonik and Shandong Vland Biotech have unveiled a strategic partnership to expand their efforts in providing gut health solutions for farm animals globally. The joint venture, Evonik Vland Biotech (Shandong) Co., Ltd., will be headquartered in Binzhou, China, and is scheduled to enter the market in early 2024. As part of the collaboration, Evonik will distribute the joint venture’s portfolio beyond the Greater China Region.
This initiative aligns with Evonik’s commitment to developing specialty nutrition solutions for poultry, swine, and ruminants. The partnership with Vland underscores Evonik’s mission to offer comprehensive system solutions within the animal feed industry, catering to its customers’ evolving needs.
Both partners will contribute their respective gut health businesses, encompassing probiotics and formulated products, to address the Greater China Region’s feed additives market, which represents over 20% of the global market. Additionally, the joint venture aims to create innovative gut health products to meet the specific needs of the region.
The objective of Evonik’s gut health solutions is to enhance the productivity of farm animals while reducing reliance on antibiotic growth promoters. Key products in this portfolio include probiotics which support and maintain the microbial balance in animal guts, bolstering their resilience.